Guardant Health, Inc. has announced a strategic collaboration with Janssen Biotech, Inc. to pursue regulatory approval and commercialization of the Guardant360® CDx as a companion diagnostic for amivantamab, an investigational EGFR-MET bispecific antibody being studied in the treatment of non-small cell lung cancer. The agreement covers the United States, Canada, Japan, and Europe. Click on the press release link below to find out more.

https://lnkd.in/gpw_938